Innovative Therapies to
Treat and Cure HDV and
Other Serious Diseases
About Us
Developing and commercializing first-in-class, well-characterized drugs for life-threatening, rare and ultra-rare diseases with high unmet medical needs and no approved therapies.
In The News
Eiger BioPharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
Active Dialogue with FDA on Potential Peginterferon Lambda COVID-19 EUA Application Phase 3 HDV D-LIVR (lonafarnib) Study Topline Data Planned by Year End Phase 3 Congenital Hyperinsulinism AVANT (avexitide) Program Initiated Approval of Zokinvy in Europe ; Partnership with AnGes in Japan Strong
July 28, 2022Eiger BioPharmaceuticals to Host Conference Call for Second Quarter 2022 Financial Results and Business Update on Thursday, August 4
- Live Conference Call and Webcast at 4:30 PM ET - PALO ALTO, Calif. , July 28, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals , Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious
July 20, 2022Eiger Receives European Approval for Zokinvy® (lonafarnib) for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies
First and only treatment approved in Europe to treat Hutchinson-Gilford progeria syndrome and processing-deficient progeroid laminopathies 1 Extended life by an average of 4.3 years in children and young adults with HGPS 2 Now approved for use in 30 European countries, following approval in the